UroGen Pharma Ltd.

NASDAQ:URGN

Biotechnology

Healthcare
$29.79 -1.22%

-$0.40 today

Market cap
$1.46B
Beta
1.62
P/E (TTM)
-12.2
EPS (TTM)
-$2.65
52W Low $12.73High $33.79

Volume 1.14M

Average 0.79M

URGN Other Current Assets

Current assets not reported separately, such as prepaid expenses.

UroGen Pharma Ltd.NASDAQ: URGN

Other Current Assets · Q1 FY2026 · quarter ended Mar 2026

Other current assets rises 38.9% from a year ago

Other current assets stood at $19.53M at the end of Q1 FY2026, up 38.9% from a year earlier and up 21.9% from the prior quarter. Over 3 fiscal years it compounded at +10.4% a year.

Context

  • Other current assets amounted to 7.7% of total assets at the end of Q1 FY2026, up 2.0 pp from a year earlier.
  • Other current assets increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether other current assets keeps rising in the next quarterly balance sheet after a +38.9% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$19.53M+21.9% QoQ
Last fiscal yearDec 2025
$16.02M+61.5% YoY
Year agoMar 2025
$14.06M+38.9% since
Other Current Assets past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+38.9%——
1 year+61.5%——
3-year CAGR+10.4%——
5-year CAGR——
10-year CAGR——

Other Current Assets history

USD · from the balance sheet

Latest · FY2025
16.02M USD
Year-over-year change
+61.5%
4-year CAGR
+90.1%

Other Current Assets vs competitors

How URGN compares with its peers on the latest reported figures

  • URGN's Mar 2026 other current assets of $19.53M is the 2nd highest of the 3 companies compared; the peer median is $11.41M.
  • Its year-over-year change of +38.9% is the lowest of 2, against a peer median of +58.7%.
  • Other current assets amounts to 7.7% of total assets for URGN, versus a peer median of 1.3%.
URGN Competitors Peer median
Other Current Assets for URGN and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
CGONCG Oncology, Inc. Common stockSep 2026$21.44M +58.7%+63.9%2.0%
URGNUroGen Pharma Ltd.Mar 2026$19.53M +38.9%+10.4%7.7%
RLMDRelmada Therapeutics, Inc.Mar 2026$1.38M ——0.6%
Peer median (excluding URGN) $11.41M+58.7%+63.9%1.3%

Competitors are the stored peer set for URGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents44.36M55.41M95M171.99M110.75M
Short-term Investments44.78M44.56M41.97M64.7M9.71M
Net Receivables11.72M12.7M15.44M20.3M33.08M
Inventory4.83M4.33M5.67M9.23M16.46M
Other Current Assets1.23M11.91M11.1M9.92M16.02M
Total Current Assets114.39M128.91M169.19M276.14M186.02M
Property, Plant & Equipment (Net)3.15M3.75M2.36M3.79M9.09M
Goodwill00000
Intangible Assets00000
Long-term Investments675K04.5M5.02M177K
Tax Assets00000
Other Non-current Assets1.53M2.96M2.26M765K5.16M
Total Non-current Assets5.36M6.71M9.13M9.58M14.43M
Total Assets119.75M135.62M178.31M285.71M200.46M
Account Payables5.79M5.53M6.51M10.93M12.14M
Short-term Debt00000
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities10.28M11.53M14.67M18.52M18.7M
Total Current Liabilities22.38M23.92M31.21M45.95M46.42M
Long-term Debt097.54M98.55M121.73M122.21M
Deferred Tax Liabilities2.84M3.02M000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities85.71M98.92M112.92M125.18M131.18M
Total Non-current Liabilities88.95M201.06M212.31M248.57M259.51M
Total Liabilities111.33M224.98M243.52M294.51M305.93M
Common Stock61K63K89K115K133K
Retained Earnings(467.32M)(577.1M)(679.35M)(806.22M)(959.72M)
Accumulated OCI(25K)(107K)12K56K19K
Other Stockholders Equity00000
Minority Interest00000
Total Equity8.41M(89.36M)(65.21M)(8.8M)(105.47M)
Total Debt398K99.12M99.4M123.39M128.33M
Net Debt(43.96M)43.72M4.39M(48.6M)17.59M

UroGen Pharma Ltd.

NASDAQ:URGN

Intrinsic Alpha fair value

Locked

Current Price

$29.79

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.